Gilead Sciences (GILD) Interest Coverage Ratio Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) Interest Coverage Ratio Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.75% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 40.80% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 29.85% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.52% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.43% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 38.88% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -296.00% |
| Mar 31, 2026 | 146.78% |
| Dec 31, 2025 | -12.08% |
| Sep 30, 2025 | 100.82% |
| Jun 30, 2025 | 103.98% |
| Mar 31, 2025 | 325.83% |
| Dec 31, 2024 | 40.68% |
| Sep 30, 2024 | 19.54% |
| Jun 30, 2024 | 105.92% |
| Mar 31, 2024 | -289.04% |
| Dec 31, 2023 | -10.58% |
| Sep 30, 2023 | 56.68% |
| Jun 30, 2023 | 31.31% |
| Mar 31, 2023 | 27.37% |
| Dec 31, 2022 | 36.54% |
| Sep 30, 2022 | 47.74% |
| Jun 30, 2022 | 56.05% |
| Mar 31, 2022 | -61.73% |
| Dec 31, 2021 | -3.91% |
| Sep 30, 2021 | -3.95% |